Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

This study will evaluate the effect of investigational drugs, pembrolizumab alone or pembrolizumab with lenvatinib, on the immune systems response to kidney cancer when given before and after surgery to remove kidney cancer.

Trial Details

NCT ID
NCT05733715
Phase
EARLY_PHASE1
Sponsor
Abramson Cancer Center at Penn Medicine
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Pembrolizumab infusion
  • Lenvatinib tablet
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of renal c…
  • Male participants are eligible to participate if they agree to the following during the intervention period and for at least 7 days after the last …
  • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to rema…
  • Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause o Agree to use a male condom plus pa…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →